The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
| Autor: | Jeffrey L. Miller, George D. Kitas, Millie Wang, Roumen Nakov, Michael E. Weinblatt, Jiri Vencovsky, Seva Panfilov, Krystyna Jedrychowicz-Rosiak, Gabriel Abreu, William B. White |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Ambulatory blood pressure Pyridines Morpholines Urology Aminopyridines Fostamatinib Placebo Risk Assessment Drug Administration Schedule law.invention Arthritis Rheumatoid Sex Factors Randomized controlled trial Double-Blind Method law Reference Values Oxazines Internal Medicine medicine Confidence Intervals Humans Aged Dose-Response Relationship Drug business.industry Age Factors Blood Pressure Monitoring Ambulatory Middle Aged Protein-Tyrosine Kinases medicine.disease Discontinuation Blood pressure Pyrimidines Treatment Outcome Rheumatoid arthritis Antirheumatic Agents Ambulatory Hypertension Multivariate Analysis Physical therapy Female Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of the American Society of Hypertension : JASH. 8(11) |
| ISSN: | 1878-7436 |
| Popis: | Clinical trials of fostamatinib in patients with rheumatoid arthritis showed blood pressure (BP) elevation using clinic measurements. The OSKIRA-ambulatory BP monitoring trial assessed the effect of fostamatinib on 24-hour ambulatory systolic BP (SBP) in patients with active rheumatoid arthritis. One hundred thirty-five patients were randomized to fostamatinib 100 mg twice daily (bid; n = 68) or placebo bid (n = 67) for 28 days. Ambulatory, clinic, and home BPs were measured at baseline and after 28 days of therapy. Primary end point was change from baseline in 24-hour mean SBP. Fostamatinib increased 24-hour mean SBP by 2.9 mm Hg (P = .023) and diastolic BP (DBP) by 3.5 mm Hg (P < .001) versus placebo. Clinic/home-measured BPs were similar to those observed with ambulatory BP monitoring. After treatment discontinuation (1 week), clinic BP values returned to baseline levels. Fostamatinib induced elevations in 24-hour mean ambulatory SBP and DBP. BP elevations resolved with fostamatinib discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|